Compare BRFH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | CVM |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 53.1M |
| IPO Year | N/A | 1987 |
| Metric | BRFH | CVM |
|---|---|---|
| Price | $2.67 | $4.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 73.4K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,574,000.00 | N/A |
| Revenue This Year | $37.56 | N/A |
| Revenue Next Year | $101.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $2.00 | $1.98 |
| 52 Week High | $6.08 | $21.93 |
| Indicator | BRFH | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 32.74 |
| Support Level | $2.53 | $4.01 |
| Resistance Level | $3.50 | $6.75 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 14.43 | 29.19 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.